EMD Serono at ASCO 2020

Virtual Scientific Program of the American Society of Clinical Oncology May 29-31, 2020

Select ASCO 2020 Abstracts

Title Lead Author Abstract # Presentation Date / Time
BAVENCIO (avelumab)
Maintenance avelumab + best supportive care (Ave + BSC) vs BSC alone after platinum-based first-line (1L) chemotherapy (CTx) in advanced urothelial carcinoma (aUC): results from the JAVELIN Bladder 100 phase 3 trial T Powles LBA1

Accepted for Plenary Session, Sunday, May 31 at 1 p.m.

Abstract available online at the ASCO Meeting Library from Thursday, May 28 at 5 p.m.

Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101 MA Bilen 5061 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.
Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping:  health-related quality of life (HRQoL) (VISION PRO) PK Paik 9575 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.
Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with NSCLC with METex14 skipping X Le 9556 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.
Bintrafusp Alfa      
Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC) BC Cho 9558 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.
A multicenter Phase Ib/II study of DNA-PK inhibitor peposertib (formerly M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer P  Romesser TPS4117 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.

EMD Serono in Oncology

Our Oncology Franchise

We understand that every person diagnosed with cancer is someone’s parent, sibling, or friend. This drives our discovery and development of medicines that matter.

Our Pipeline

Browse the programs in our pipeline to see what we're currently working on by phase, therapeutic area and compound type.

Global Pipeline

Julissa Viana

EMD Serono Media Contact


You have accessed https://www.emdserono.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Site Exit Disclaimer

You are now leaving the website of EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany. This link will either lead to a different website maintained by EMD Serono/its global business, or a different website/resource maintained by 3rd parties.

If you are visiting a 3rd party website, we have no control over the content and are not responsible for and make no representation as to the accuracy or any other aspect of such resource or the privacy practices of such 3rd party. Providing links to a 3rd party website does not constitute EMD Serono’s endorsement of such website or the information or products presented on such website. 

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement